China Pharma Holdings
CPHI
4 hedge funds and large institutions have $92.7K invested in China Pharma Holdings in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.
6% more capital invested
Capital invested by funds: $87.3K → $92.7K (+$5.39K)
0.09% more ownership
Funds ownership: 0% → 0.09% (+0.09%)
43% less funds holding
Funds holding: 7 → 4 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$111K |
| 2 |
Millennium Management
New York
|
+$23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$7.58K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$5.64K |
| 3 |
Two Sigma Advisers
New York
|
-$2.2K |
CPHI Hedge Fund Activity: Q1 2023 in Review
4 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q1 2023, worth a combined $92.7K — up 6.2% from $87.3K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CPHI and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $111K. The largest seller was UBS Group, exiting entirely with an estimated $7.58K sold.
- 4 institutional investors held China Pharma Holdings (CPHI) as of Q1 2023, down from 7 in Q4 2022.
- Funds reported $92.7K of China Pharma Holdings stock for Q1 2023, up 6.2% quarter-over-quarter.
- 0 funds opened new China Pharma Holdings positions in Q1 2023 and 3 closed out, a net change of -3 holders.
- The largest China Pharma Holdings buyer in Q1 2023 was Renaissance Technologies, an estimated $111K added.
- The largest China Pharma Holdings seller in Q1 2023 was UBS Group, an estimated $7.58K sold.
Based on aggregated 13F filings for Q1 2023.